Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDM Aradigm Corporation daily Stock Chart
ARDM [NASD]
Aradigm Corporation
Index- P/E- EPS (ttm)-0.98 Insider Own0.70% Shs Outstand15.33M Perf Week-66.05%
Market Cap31.12M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float8.72M Perf Month-63.29%
Income-14.50M PEG- EPS next Q-0.25 Inst Own35.70% Short Float3.95% Perf Quarter-60.27%
Sales12.20M P/S2.55 EPS this Y-91.00% Inst Trans8.66% Short Ratio1.05 Perf Half Y42.96%
Book/sh-0.62 P/B- EPS next Y45.90% ROA-80.20% Target Price10.00 Perf Year6.84%
Cash/sh0.82 P/C2.47 EPS next 5Y- ROE263.90% 52W Range0.78 - 7.35 Perf YTD-69.70%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-211.40% 52W High-72.39% Beta9.58
Dividend %- Quick Ratio1.70 Sales past 5Y-24.40% Gross Margin- 52W Low160.26% ATR0.67
Employees23 Current Ratio1.70 Sales Q/Q5356.00% Oper. Margin-88.70% RSI (14)25.37 Volatility27.15% 14.01%
OptionableYes Debt/Eq- EPS Q/Q52.80% Profit Margin- Rel Volume0.99 Prev Close2.06
ShortableYes LT Debt/Eq- EarningsFeb 01 BMO Payout- Avg Volume328.97K Price2.03
Recom1.00 SMA20-61.36% SMA50-54.27% SMA200-19.38% Volume323,338 Change-1.46%
Jan-12-18Downgrade Ladenburg Thalmann Buy → Neutral
Jan-17-18 04:00PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aradigm Corporation - ARDM ACCESSWIRE
08:00AM  ARDM INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aradigm Corporation Business Wire
Jan-16-18 02:03PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Aradigm Corporation (Nasdaq: ARDM) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire -8.85%
12:52PM  ARDM SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aradigm Corporation Business Wire
10:10AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018 GlobeNewswire
Jan-15-18 12:20PM  INVESTOR ALERT: Holzer & Holzer Announces Class Action Lawsuit Filed on Behalf of Investors in Aradigm Business Wire
12:00PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aradigm Corporation Business Wire
Jan-14-18 12:44PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Aradigm Corporation GlobeNewswire
Jan-12-18 08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aradigm Corporation (ARDM) GlobeNewswire -33.92%
05:05PM  ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Aradigm Corporation To Contact The Firm ACCESSWIRE
02:42PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aradigm Corporation -- ARDM Business Wire
12:50PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aradigm Corporation Business Wire
12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:30AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018 PR Newswire
09:04AM  Biotech Updates: Aradigm Corporation & Puma Biotechnology Market Exclusive
Jan-11-18 06:03PM  Pomerantz Law Firm Announces the Filing of a Class Action against Aradigm Corporation and Certain Officers ARDM GlobeNewswire
04:53PM  Aradigm Reports Results of FDA Advisory Committee Meeting on Linhaliq GlobeNewswire
Jan-10-18 04:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aradigm Corporation - ARDM PR Newswire -7.57%
04:01PM  ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Aradigm Corporation To Contact The Firm PR Newswire
Jan-09-18 04:20PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Aradigm Corporation ARDM Business Wire -38.13%
03:59PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aradigm Corporation (ARDM) PR Newswire
Jan-04-18 11:10AM  Where Aradigm Corporation (NASDAQ:ARDM) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
Jan-03-18 09:28AM  The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals Zacks -6.61%
Jan-02-18 08:04AM  3 Biotech and Pharma Stocks with FDA Catalysts this January Zacks
Dec-30-17 10:19AM  Attention Biotech Investors: Brace For These January PDUFA Events Benzinga
Dec-27-17 10:59AM  ETFs with exposure to Aradigm Corp. : December 27, 2017 Capital Cube +8.41%
Dec-22-17 11:09AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aradigm Corporation Business Wire
Dec-12-17 12:45PM  ETFs with exposure to Aradigm Corp. : December 12, 2017 Capital Cube +6.84%
Dec-01-17 10:25AM  ETFs with exposure to Aradigm Corp. : December 1, 2017 Capital Cube
07:00AM  Aradigm Announces FDA Advisory Committee Meeting for Linhaliq Business Wire
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 11:39AM  ETFs with exposure to Aradigm Corp. : November 20, 2017 Capital Cube
Nov-08-17 05:36PM  ETFs with exposure to Aradigm Corp. : November 8, 2017 Capital Cube -5.66%
Nov-07-17 08:11AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube +10.42%
07:00AM  Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City Business Wire
Nov-02-17 08:23AM  Aradigm reports 3Q loss Associated Press -8.31%
07:00AM  Aradigm Announces Third Quarter 2017 Financial Results Business Wire
Oct-16-17 06:40AM  Aradigm (ARDM) Shares March Higher, Can It Continue? Zacks -5.87%
Oct-10-17 09:15AM  New Research Coverage Highlights Aradigm, Social Reality Inc, Rentech, PayPal, JPMorgan Chase, and Helios and Matheson Analytics ­Consolidated Revenues, Company Growth, and Expectations GlobeNewswire +18.65%
07:00AM  Aradigm Regains Compliance with NASDAQ Listing Requirements Business Wire
Oct-09-17 01:39PM  Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns? Simply Wall St.
Sep-27-17 08:00AM  Aradigm, NDA for Linhaliq Accepted by FDA With Priority Review, Catalyst and Pipeline Review ACCESSWIRE -10.83%
07:00AM  Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq ACCESSWIRE
Sep-25-17 07:00AM  Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status Business Wire +32.81%
Sep-22-17 07:00AM  Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26 Business Wire +29.08%
Sep-15-17 07:00AM  Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients Business Wire
Sep-05-17 07:00AM  Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress Business Wire
Aug-15-17 07:00AM  Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq Business Wire -8.45%
Aug-10-17 11:51PM  Aradigm posts 2Q profit Associated Press
07:00AM  Aradigm Announces Second Quarter 2017 Financial Results Business Wire
Jul-27-17 08:00AM  Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis Business Wire
May-15-17 07:06AM  Aradigm reports 1Q loss Associated Press
07:00AM  Aradigm Announces First Quarter 2017 Financial Results Business Wire
Mar-30-17 05:05PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mar-28-17 07:14AM  Aradigm reports 4Q loss Associated Press
07:00AM  Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results Business Wire
Feb-09-17 07:00AM  Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 Business Wire +6.77%
Jan-06-17 07:00AM  Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9 Business Wire +6.06%
Dec-16-16 07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers at Insider Monkey -7.14%
Dec-02-16 05:02PM  ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -5.24%
04:29PM  Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Investopedia
04:29PM  Aradigm Lung Infection Antibiotic Fails Trial (ARDM) at Investopedia
01:23PM  Dont Write Off Aradigm Corporation (ARDM) Just Yet Insider Monkey
01:23PM  Dont Write Off Aradigm Corporation (ARDM) Just Yet at Insider Monkey
Dec-01-16 11:56AM  Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin TheStreet.com -56.30%
11:56AM  Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin at TheStreet
08:41AM  Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials at MarketWatch
07:47AM  Aradigm posts mixed late-stage data on inhaled antibiotic Reuters
07:00AM  Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa Business Wire
Nov-18-16 01:04PM  ARADIGM CORP Financials
Nov-10-16 04:42PM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
11:20AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Capital Cube
11:20AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
07:00AM  Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Business Wire
Nov-09-16 05:25PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.57%
07:08AM  Aradigm reports 3Q loss
07:00AM  Aradigm Announces Third Quarter 2016 Financial Results Business Wire
Oct-18-16 07:00AM  Multi-million Dollar DTRA Funding for Biodefense Research with Aradigms Inhaled Ciprofloxacin Business Wire
Oct-07-16 07:00AM  Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms Business Wire
Sep-22-16 09:11AM  3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock +19.96%
07:00AM  Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients Business Wire
Sep-21-16 07:00AM  Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City Business Wire
05:49AM  Aradigm (ARDM) Shares March Higher, Can It Continue?
Sep-20-16 07:00AM  Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 Business Wire
Aug-12-16 11:23AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 07:04AM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
Aug-10-16 05:17PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:05AM  Aradigm reports 2Q loss
07:00AM  Aradigm Announces Second Quarter 2016 Financial Results Business Wire
Jun-10-16 05:02PM  ARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-24-16 01:49PM  The Sub Dollar Stock In The 800 Billion Cigarette Industry The Tobacco Giants Need To Stay Relevant -6.88%
May-17-16 12:15PM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers
May-11-16 07:00AM  Two Presentations on Aradigms Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference Business Wire
May-10-16 05:45PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:45PM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
09:03AM  Aradigm reports 1Q loss
07:00AM  Aradigm Announces First Quarter 2016 Financial Results Business Wire
Apr-29-16 09:42AM  Activist Starboard Value Gets Seats on Marvell Technology Group Ltd. (MRVL)s Board; Two Other Hedge Funds Disclose Latest Moves at Insider Monkey
Apr-28-16 04:08PM  ARADIGM CORP Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online -7.02%
Apr-27-16 04:30PM  ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio EDGAR Online
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Froehlich Juergen KurtChief Medical OfficerApr 04Sale1.513,7655,68585,129Apr 06 01:06 PM